Suppression of tumor growth by a heterologous antibody directed against multiple myeloma dominant CD38 antigen in SCID mice injected with multiple myeloma cells
Affiliations: [a] Department of Surgery, University of Calgary, Calgary, AB, Canada | [b] Department of Neurosurgery, University of Utah, Salt Lake City, UT, USA | [c] Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA
Correspondence:
[*]
Corresponding author: Arpad Z. Barabas, Department of Surgery, B702 Health Sciences Centre, 3330 Hospital Dr. NW, University of Calgary, Calgary, AB, Canada T2N 4N1. Tel.: +1 403 220 8901; Fax: +1 403 270 8795; E-mail:barabas@ucalgary.ca
Abstract: Employing passive immunization - using a heterologous anti-CD38 IgG
antibody containing serum - in SCID mice injected subcutaneously with human
multiple myeloma cells, we have shown that treatments with the antiserum -
especially in the presence of complement - significantly decreased cancer
growth. However, administered antibody and complement was not sufficient in
amount to prevent cancer cell multiplication and cancer growth expansion to
a satisfactory degree. Larger volumes of the same components more than
likely would have further reduced cancer growth and prolonged the life of
mice. In control mice, cancer growth progressed faster proving that lytic
immune response against multiple myeloma cells is necessary for cancer cell
kill.
